hum0327-v1Release info

Screening of neoantigens and neoantigen reactive T cell receptors in hepatobiliary and pancreatic cancer for clinical application of personalized T cell therapy

Aims

Cancers in the hepatobiliary and pancreatic regions are not only common but also difficult to cure. Recently, it has been reported that mutant peptides newly generated by genetic mutations are recognized by the immune system as neoantigens, and the development of immunotherapy targeting these peptides has been promoted. In this study, in order to develop effective immunotherapy for hepatobiliary and pancreatic cancers and to propose it as a new cancer therapy, we will first identify different genetic mutations and antigens in each patient with these cancers, and then verify the practicality of immunotherapy using a diverse population of T cells that recognize them.

Methods

Paired fresh normal and tumor tissues were collected from surgically resected HCC and mCRC. RNA and genomic DNA were extracted from tumor/normal tissues (2-5 mm in diameter) and used for whole exome sequencing or RNA sequencing with NextSeq 550 (Illumina).

Participants/materials

Tumor tissues were collected from liver cancer patients, who were received surgical resection at the National Cancer Center Hospital East (NCCE) between 2017 and 2020.

URL

N/A

Principal investigator

Toshihiro Suzuki

Affiliation

Division of Cancer Immunotherapy, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center